IMGN Share Price

Open 4.32 Change Price %
High 4.49 1 Day -0.03 -0.69
Low 4.22 1 Week 0.11 2.63
Close 4.30 1 Month 0.58 15.59
Volume 2266388 1 Year -4.20 -49.41
52 Week High 8.79
52 Week Low 1.51
IMGN Important Levels
Resistance 2 4.55
Resistance 1 4.45
Pivot 4.34
Support 1 4.15
Support 2 4.05
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
SIRI 5.11 -1.73%
STX 42.01 -16.83%
More..
NASDAQ USA Top Gainers Stocks
SPIR 0.02 100.00%
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
CMLS 0.28 21.74%
ZAZA 0.06 20.00%
CONN 17.50 18.24%
CONN 17.50 18.24%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
PGRX 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

ImmunoGen, Inc. (NASDAQ: IMGN)

IMGN Technical Analysis 4
As on 26th Apr 2017 IMGN Share Price closed @ 4.30 and we RECOMMEND Buy for LONG-TERM with Stoploss of 2.90 & Strong Buy for SHORT-TERM with Stoploss of 3.33 we also expect STOCK to react on Following IMPORTANT LEVELS.
IMGN Target for April
1st Target up-side 4.34
2nd Target up-side 4.67
3rd Target up-side 5
1st Target down-side 3.4
2nd Target down-side 3.07
3rd Target down-side 2.74
IMGN Other Details
Segment EQ
Market Capital 957291648.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.immunogen.com
IMGN Address
IMGN
830 Winter Street
Waltham, MA 02451
United States
Phone: 781-895-0600
Fax: 781-895-0611
Interactive Technical Analysis Chart ImmunoGen, Inc. ( IMGN NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ImmunoGen, Inc.
IMGN Business Profile
ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company�s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company's TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.